Arvinas Inc
ARVN
ISIN null / Valor 43526042
Arvinas Inc
UMushroom community rating:
About company
Arvinas Inc is a biopharmaceutical company focused on developing innovative therapies for cancer and other challenging diseases using its proprietary PROTAC (proteolysis-targeting chimera) technology. This approach leverages the body’s natural protein degradation systems to selectively identify and eliminate disease-causing proteins, offering a novel mechanism of action compared to traditional therapies. By targeting proteins that are otherwise difficult to modulate with existing treatments, Arvinas aims to address unmet medical needs and advance the treatment landscape in oncology and related fields. The company's commitment to pioneering protein degradation strategies positions it as a leader in the development of next-generation therapeutics.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
679 M
Market cap (USD)
722,403
Daily traded volume (Shares)
19.14 / 18.365
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Lieselotte Dathe
EQUITIES OF THE SAME SECTOR
